Emerging Heart Failure Therapies in 2026: GLP-1s, Nonsteroidal MRAs, and Precision Care

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a broader, more individualized approach to care that extends beyond traditional guideline-directed medical therapy.

Recent reviews and clinical updates suggest that metabolic therapies, nonsteroidal mineralocorticoid receptor antagonists (MRAs), and precision-based phenotyping may redefine how clinicians manage patients across the HF spectrum, particularly those with preserved and mildly reduced ejection fraction.¹

These developments arrive as HF prevalence continues to rise globally, increasing pressure on health systems and payers to identify therapies that improve outcomes while reducing hospitalization burden and overall health care utilization.

GLP-1 Therapies Gain Momentum

Among the most closely watched developments is the expanding role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular disease (CVD) management.

Although initially developed for type 2 diabetes and obesity, newer evidence suggests these agents may also provide benefits in HF populations, particularly among patients with obesity-related HF with preserved ejection fraction (HFpEF).

Investigators have pointed to reductions in inflammation, weight burden, and cardiometabolic stress as potential mechanisms driving improved functional outcomes.

The growing interest follows findings from the STEP-HFpEF (NCT04916470) trial, which demonstrated that semaglutide improved symptoms, exercise capacity, and quality of life in patients with obesity-related HFpEF.²

Together, these data are fueling broader discussions about whether HF management should increasingly incorporate metabolic disease treatment strategies alongside traditional cardiac therapies.

Nonsteroidal MRAs Expand Therapeutic Options

Another major area of focus involves nonsteroidal mineralocorticoid receptor agonists (MRAs), which are being evaluated as potentially safer alternatives to older steroidal agents such as spironolactone.

According to a recent 2026 heart failure evidence review, these next-generation therapies may reduce fibrosis and adverse cardiac remodeling while lowering the risk of hyperkalemia that has historically limited broader MRA use.¹

This shift is particularly important in older HF populations, where renal dysfunction and polypharmacy frequently complicate medication management.

Researchers note that while traditional renin-angiotensin-aldosterone system inhibition remains foundational in HF with reduced ejection fraction (HFrEF), newer therapies may enable more personalized treatment pathways based on comorbidity profiles and disease phenotype.

Precision Phenotyping Is Reshaping Heart Failure Classification

The emerging evidence also reflects a broader movement toward precision-based HF care.

Rather than relying exclusively on left ventricular ejection fraction (LVEF), clinicians are increasingly considering biomarkers, imaging characteristics, metabolic status, and inflammatory pathways when selecting therapies.

This evolution aligns with recent recommendations from the Heart Failure Society of America and the European Society of Cardiology, both of which have emphasized more granular HF phenotyping in recent scientific statements and guideline updates.³

Experts argue that these approaches may help explain why some patients respond differently to therapies despite similar ejection fraction measurements.

Managed Care Implications

For managed care organizations, the expanding HF pipeline could create both opportunities and challenges.

Novel therapies may improve long-term outcomes and reduce hospitalization rates, but they also raise questions about formulary management, prior authorization policies, and affordability.

As HF care becomes increasingly individualized, health systems may need to adapt quality metrics and reimbursement models to support phenotype-driven treatment decisions rather than standardized therapy algorithms alone.

At the same time, the growing overlap between cardiovascular, metabolic, and renal disease management may accelerate integrated care strategies across specialty areas.

References

1. Liori S, Kapelios CJ, Savarese G, et al. Heart failure evidence update 2026. Heart Fail Rev. 2026;31(1):34. doi:10.1007/s10741-026-10609-3

2. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394-1407. doi:10.1056/NEJMoa2313917

3. Steinzor P. HFSA calls for reclassification of HFmrEF as a distinct heart failure phenotype. AJMC^®. May 20, 2026. Accessed May 21, 2026. https://www.ajmc.com/view/hfsa-calls-for-reclassification-of-hfmref-as-a-distinct-heart-failure-phenotype